Patents by Inventor The University of North Carolina at Chapel Hill
The University of North Carolina at Chapel Hill has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20140264001Abstract: A miniature electrode apparatus is disclosed for trapping charged particles, the apparatus including, along a longitudinal direction: a first end cap electrode; a central electrode having an aperture; and a second end cap electrode. The aperture is elongated in the lateral plane and extends through the central electrode along the longitudinal direction and the central electrode surrounds the aperture in a lateral plane perpendicular to the longitudinal direction to define a transverse cavity for trapping charged particles.Type: ApplicationFiled: March 15, 2013Publication date: September 18, 2014Applicant: THE UNIVERSITY OF NORTH CAROLINA OF CHAPEL HILLInventor: THE UNIVERSITY OF NORTH CAROLINA OF CHAPEL HILL
-
Publication number: 20140072632Abstract: The presently disclosed subject matter describes the use of fluorinated elastomer-based materials, in particular perfluoropolyether (PFPE)-based materials, in high-resolution soft or imprint lithographic applications, such as micro- and nanoscale replica molding, and the first nano-contact molding of organic materials to generate high fidelity features using an elastomeric mold. Accordingly, the presently disclosed subject matter describes a method for producing free-standing, isolated nanostructures of any shape using soft or imprint lithography technique.Type: ApplicationFiled: March 28, 2013Publication date: March 13, 2014Applicant: The University of North Carolina at Chapel HillInventor: The University of North Carolina at Chapel Hill
-
Publication number: 20130338040Abstract: This invention is directed to a method to increased likelihood of brain metastasis from NSCLC in a subject by measuring the levels of LKB1. The invention also provides related kits.Type: ApplicationFiled: April 16, 2013Publication date: December 19, 2013Inventor: The University of North Carolina at Chapel Hill
-
Publication number: 20130281539Abstract: Highly selective 5-HT(2C) receptor agonists receptors are disclosed. The 5-HT(2C) receptor agonists are used in the treatments of disease and conditions wherein modulation of 5-HT(2C) receptors provides a benefit, such as obesity and psychiatric disorders.Type: ApplicationFiled: May 6, 2013Publication date: October 24, 2013Inventors: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS, THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL
-
Publication number: 20130225658Abstract: The presently disclosed subject matter provides methods and compositions for modulating gene expression in myocytes. Also provided are cells comprising the compositions of the presently disclosed subject matter.Type: ApplicationFiled: March 8, 2013Publication date: August 29, 2013Applicant: THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILLInventor: The University of North Carolina at Chapel Hill
-
Publication number: 20130225665Abstract: The presently disclosed subject matter provides methods and compositions for modulating gene expression in myocytes. Also provided are cells comprising the compositions of the presently disclosed subject matter.Type: ApplicationFiled: March 8, 2013Publication date: August 29, 2013Applicant: THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILLInventor: THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL
-
Publication number: 20130225629Abstract: The presently disclosed subject matter generally relates to methods and compositions for treating enteritis. More particularly, the presently disclosed subject matter relates to methods and compositions for modulating a component of a PI3K/mTOR pathway. In some embodiments, the methods and compositions of the presently disclosed subject matter generally relates to the treatment of campylobacteriosis. More particularly, the methods and compositions of the presently disclosed subject matter relate to the treatment of campylobacteriosis by modulating a component of a PI3K/mTOR pathway.Type: ApplicationFiled: February 25, 2013Publication date: August 29, 2013Applicant: THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILLInventor: THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL
-
Publication number: 20130209438Abstract: Methods and compositions are provided for the treatment of pain and cystic fibrosis. The methods include administering to an animal a composition or a pharmaceutical formulation comprising a therapeutically effective amount of a Prostatic Acid Phosphatase (“PAP”) polypeptide, or an active variant, fragment or derivative thereof, or a therapeutically effective amount of an activity enhancing PAP modulator. PAP is provided as a treatment for chronic pain including neuropathic and inflammatory pain in animals and humans. The PAP, or the active variant, fragment or derivative thereof, or the activity enhancing modulator of the PAP is administered via one or more of injection, intrathecal injection, oral administration, a surgically implanted pump, stem cells, viral gene therapy, or naked DNA gene therapy. Intrathecal injection of PAP functions as an analgesic and reduces thermal sensitivity in mice. PAP can reduce chronic mechanical and thermal inflammatory pain in mice.Type: ApplicationFiled: April 23, 2013Publication date: August 15, 2013Applicant: The University of North Carolina at Chapel HillInventors: The University of North Carolina at Chapel Hill, Pirkko Vihko
-
Publication number: 20130203799Abstract: Although it can be farnesylated, the mutant lamin A protein expressed in Hutchinson Gilford Progeria Syndrome (HGPS) cannot be defarnesylated because the characteristic mutation causes deletion of a cleavage site necessary for binding the protease ZMPSTE24 and effecting defarnesylation. The result is an aberrant farnesylated protein (called “progerin”) that alters normal lamin A function as a dominant negative, as well as assuming its own aberrant function through its association with the nuclear membrane. The retention of farnesylation, and potentially other abnormal properties of progerin and other abnormal lamin gene protein products, produces disease. Farnesyltransferase inhibitors (FTIs) (both direct effectors and indirect inhibitors) will inhibit the formation of progerin, cause a decrease in lamin A protein, and/or an increase prelamin A protein. Decreasing the amount of aberrant protein improves cellular effects caused by and progerin expression.Type: ApplicationFiled: April 4, 2013Publication date: August 8, 2013Applicants: The Government of the United States of America as represented by the Secretary of the Department of, The University of North Carolina at Chapel Hill, The Regents of the University of Michigan, Progeria Research Foundation, Inc.Inventors: The Government of the United States of America as represented by the Secretary of the Department, Progeria Research Foundation, Inc., The Regents of the University of Michigan, The University of North Carolina at Chapel Hill
-
Publication number: 20130196867Abstract: The present invention generally relates to combinatorial post-translationally-modified histone peptides and arrays thereof. The invention further relates to methods of using the same.Type: ApplicationFiled: December 14, 2012Publication date: August 1, 2013Applicant: The University of North Carolina at Chapel HillInventor: The University of North Carolina at Chapel Hill
-
Publication number: 20130197924Abstract: A method for evaluating a hospital patient's risk of mortality includes collecting data from physiologic signals generated by patient monitors, physiologic signals of organ function, and demographic information for a patient. A measure of the variability of at least one of the physiologic signals is determined. Data and the measure of variability are analyzed to determine whether a value for a particular physiologic or demographic variable falls within a critical interval for the variable that indicates that the value is predictive of mortality or survival. Each time a value for a physiological or demographic variable for the patient falls within a critical interval, the occurrence of an event for the patient is recorded. The number of events for the patient is counted over a time period. Output perceptible by human user that indicates the patient's risk of mortality or likelihood of survival is generated based on the count.Type: ApplicationFiled: December 19, 2012Publication date: August 1, 2013Applicant: THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILLInventor: The University of North Carolina at Chapel Hill
-
Publication number: 20130196951Abstract: The present invention is directed to compositions comprising at least one nitric oxide donor and at least one second therapeutically active agent with antimicrobial or wound healing capability. In one embodiment, the nitric oxide donor is a nanoparticle which is designed to control for the amount and duration of release of nitric oxide. The nanoparticle may further comprise the additional therapeutically active agent. The composition is useful for enhancing wound healing and for treating and preventing microbial infection. In one embodiment, the composition is directed toward reducing oral bacteria or dental plaque. The combination of one or more nitric oxide donors and one or more additional therapeutically active agent results in unexpected synergistic effects, wherein both the antimicrobial efficacy of the nitric oxide and the antimicrobial or wound healing efficacy of the second therapeutically active agent are enhanced.Type: ApplicationFiled: March 11, 2013Publication date: August 1, 2013Applicant: UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILLInventor: UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL
-
Publication number: 20130177921Abstract: The present invention relates to methods of assessing damage to cellular DNA including the type, frequency and/or distribution of the DNA damage in the genome. The invention further provides methods of evaluating DNA damage in a cell caused by an agent and/or event as well as methods of determining a subject's prior exposure to an agent and/or event that is known or suspected to cause DNA damage. Further provided are methods of determining whether a subject is at an increased risk for a disease or disorder as a result of cellular DNA damage.Type: ApplicationFiled: November 26, 2012Publication date: July 11, 2013Applicant: The University of North Carolina at Chapel HillInventor: The University of North Carolina at Chapel Hill
-
Publication number: 20130131678Abstract: Devices and methods for treating fractures using intramedullary nails and screws are provided. An intramedullary nail and fixation device can be capable of holding a bone out to length when it is broken in a manner that allows shortening of and/or compressing a bone to promote healing. The device can include a flexible nail with a first leading end and a second end, the nail having a threaded outer surface along at least a portion of a length of the nail. A method for treatment of fractures of long bones having a medullary canal can include creating a hole into an end of a bone to be compressed, inserting a leading end of such a flexible nail into the hole, and rotating the nail to advance the nail through the medullary canal.Type: ApplicationFiled: November 29, 2012Publication date: May 23, 2013Applicant: THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILLInventor: THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL
-
Publication number: 20130125714Abstract: Screw driver-holder apparatuses, systems and methods are provided and can include a screw and a screwdriver. The screw can include a threaded screw body and a screw head, and the screw head can include a socket and a screw head surface surrounding the socket. The screwdriver can include a hollow sleeve with a longitudinal bore and a first end defining a screw engagement surface and a driving shaft positioned within the longitudinal bore of the hollow sleeve and rotatable relative to the hollow sleeve. The driving shaft can further include a first end extending beyond the first end of the hollow sleeve, a second end opposite the first end, and a stop restricting axial movement of the sleeve towards the second end of the driving shaft. The first end can include a protruding tip adapted for engaging the socket of the screw head.Type: ApplicationFiled: November 29, 2012Publication date: May 23, 2013Applicant: THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILLInventor: THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL
-
Publication number: 20130123097Abstract: A method of converting at least one first alkane to a mixture of at least one low molecular weight alkane (optionally also including additional lower and/or higher molecular weight alkanes) and at least one high molecular weight alkane, comprises: reacting a first alkane in the presence of dual catalyst system comprising a first catalyst (i.e., a hydrogen transfer catalyst) and a second catalyst (i.e., a metathesis catalyst) to produce a mixture of low and high molecular weight alkanes.Type: ApplicationFiled: December 20, 2012Publication date: May 16, 2013Applicant: The University of North Carolina at Chapel HillInventor: The University of North Carolina at Chapel Hill
-
Publication number: 20130101505Abstract: The present invention provides radiotherapeutic agents and compositions and methods for making and using the same. In some embodiments, the radiotherapeutic agent is a nanoparticle comprising a radionuclide and a carrier moiety. In some embodiments, the radionuclide is produced by activating a stable activatable particle via neutron activation.Type: ApplicationFiled: October 25, 2012Publication date: April 25, 2013Applicant: The University of North Carolina at Chapel HillInventor: The University of North Carolina at Chapel Hill
-
Publication number: 20130084575Abstract: The present invention provides an apparatus comprising, in combination: (a) a cell culture plate, the cell culture plate comprising a first substrate and a plurality of cell carriers on the substrate in a first pattern; and (b) a cell replication plate, the cell replication plate comprising a second substrate and a plurality of cell sampling posts on the second substrate in a second pattern corresponding to the first pattern. Each of the sampling posts is configured to align with a respective one of the cell carriers in a position in which cells growing on the cell carrier propagate onto the sampling post; so that a plurality of distinct cell colonies growing on the cell culture plate are replicated on the cell replication plate. Methods of using the same are also described.Type: ApplicationFiled: September 28, 2012Publication date: April 4, 2013Applicant: The University of North Carolina at Chapel HillInventor: The University of North Carolina at Chapel Hill